- Cancer Type
- Sample Type
- Results Expected
What is FoundationACT?
FoundationACT is a blood-based circulating tumor DNA (ctDNA) assay for solid tumors that identifies clinically relevant genomic alterations driving the growth of a patient's cancer. This liquid biopsy can help physicians identify treatment options by providing clinically actionable information relevant to diagnosis, risk-stratification, and prognosis. Test results provide information about potential targeted therapies and/or available clinical trials to better inform treatment decisions.
FoundationACT is validated to detect all classes of genomic alterations and to analyze more than 60 of the most commonly mutated genes in solid tumors using only a blood sample.
- A single assay that detects all 4 classes of genomic alterations required to comprehensively profile a tumor.
- Identification of resistance mutations or fusions in lung cancer§
- Can be integrated with solid tissue testing results to give a more complete picture of the evolution of a patient’s tumor
- Requires only two 8.5mL tubes of blood
† 99% PPV for all alterations, calculated as a weighted average of the PPV for each class of alteration, with the weighting based upon the frequency with which each class is detected. The PPV for base substitutions, indels, rearrangements, and copy number variations, each independently, are 99.9%, 98.8%, 98.0%, and 97.6%, respectively.
‡ >99% sensitivity for base substitutions, indels, and rearrangements at ≥ 1% MAF. Sensitivity for base substitutions at >0.5% MAF is 98.9% and sensitivity for copy number variations is >95% when the tumor fraction is ≥ 20%.
§ Ou SI, Young L, Schrock AB, Johnson A, Klempner SJ, Zhu VW, Miller VA, Ali SM. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping Journal of Thoracic Oncology (2017)